FGFR3-IN-12
FGFR3-IN-12 is a selective fibroblast growth factor receptor 3 (FGFR3) inhibitor with an IC50 of 6.8 nM. FGFR3-IN-12 shows an IC50 of 19.2 nM against FGFR3V555M and an IC50 of 16.9 nM against TNK1 (Thirty-eight Negative Kinase 1). FGFR3-IN-12 inhibits cancer cells proliferation and induces caspase-mediated apoptosis. FGFR3-IN-12 exhibits antitumor activity in bladder cancer xenografts mice models. FGFR3-IN-12 can be used for the research of cancer, such as bladder cancer.
For research use only. We do not sell to patients.
- CAS No.: 3127143-52-3
- Formula: C26H30N8O2
- Molecular Weight:486.57
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Caspase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
FGFR3 6.8 nM (IC50) |
FGFR3V555M 19.2 nM (IC50) |
FGFR2 35.7 nM (IC50) |
FGFR1 296.2 nM (IC50) |
FGFR4 414.5 nM (IC50) |
Caspase-3 |
Caspase-7 |
In Vitro
FGFR3-IN-12 (Compound 10s) potently inhibits wild-type FGFR3 with an IC50 of 6.8 nM, and exhibits 5 to 60-fold selectivity over wild-type FGFR1, FGFR2, and FGFR4[1].
FGFR3-IN-12 (30 min) inhibits the FGFR3V555M mutant with an IC50 of 19.2 nM[1].
FGFR3-IN-12 (5 days) potently inhibits proliferation of FGFR3-driven RT112/84 bladder carcinoma cells with an IC50 of 9.2 nM, and exhibits 3.2- to 48.6-fold selectivity over FGFR1-amplified, FGFR2-mutant, and FGFR4-mutant cancer cell lines[1].
FGFR3-IN-12 (0.5 μM) displays extraordinary kinome selectivity and potently inhibits TNK1 with an IC50 of 16.9 nM[1].
FGFR3-IN-12 (1 h) covalently binds to recombinant FGFR3, forming an adduct after 1 h incubation at a 1:2 (FGFR3:FGFR3-IN-12) molar ratio[1].
FGFR3-IN-12 (2 h) covalently modifies the Cys482 residue in the FGFR3 kinase domain after 2 h incubation at a 1:5 (FGFR3:FGFR3-IN-12) molar ratio[1].
FGFR3-IN-12 (6.25-100 nM; 6-48 h) concentration-dependently inhibits FGFR3 signaling and induces apoptosis in RT112/84 bladder carcinoma cells and inhibits FGFR3V555M signaling in engineered Ba/F3 cells[1].
FGFR3-IN-12 (20-80 nM; 96 h) concentration-dependently activates Caspase-3/7 in RT112/84 bladder carcinoma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RT112/84 bladder carcinoma cells, Ba/F3-FGFR3V555M engineered cells
-
Concentration:6.25-100 nM (RT112/84 cells); 5-80 nM (Ba/F3-FGFR3V555M cells)
-
Incubation Time:48 h (RT112/84 cells); 6 h (Ba/F3-FGFR3V555M cells)
-
Result:Caused a concentration-dependent reduction in phosphorylated FGFR3, phosphorylated ERK, and phosphorylated AKT in RT112/84 cells, with no change in total FGFR3, ERK, or AKT levels.
Induced concentration-dependent cleavage of PARP and activation of Caspase-7 in RT112/84 cells.
Caused a concentration-dependent reduction in phosphorylated FGFR3, phosphorylated MAPK, and phosphorylated AKT in Ba/F3-FGFR3V555M cells, with no change in total FGFR3, MAPK, or AKT levels.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/C nude with RT112/84 bladder cancer xenografts (female, 4 weeks old)[1]
-
Dosage:20 mg/kg; 40 mg/kg
-
Administration:I.p.; daily for 15 days
-
Result:Achieved 43.5% tumor growth inhibition at 20 mg/kg.
Achieved 77.1% tumor growth inhibition at 40 mg/kg.
Reduced tumor weight significantly relative to controls at both doses, with greater efficacy at 40 mg/kg.
Caused no significant body weight loss (>10%) or overt toxicity during treatment.
Suppressed Ki-67 staining in a dose-dependent manner, indicating reduced tumor cell proliferation.
Chemical Information
-
CAS No. 3127143-52-3
-
Molecular Weight 486.57
-
Formula C26H30N8O2
-
SMILES
CN1C2=C(C(C3=NC(NC4=C(N(N=C4)CCN5CCOCC5)C)=NC=C3)=C1)C=CC(NC(C=C)=O)=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)